New Delhi: After initially rejecting the government’s offer, Cipla has approached the Indian Council of Medical Research (ICMR) for non-exclusive licenses to produce the antibody testing kit developed by the National Institute of Virology in Pune, ICMR said on Thursday.
The Mumbai-based pharmaceutical giant and a Delhi-based firm NextGen Life Science Pvt Ltd have now approached the country’s apex biomedical research body to get non-exclusive licenses to produce the critical ELISA test kits, ICMR said.
ELISA, which is an abbreviation of enzyme-linked immunosorbent assay, is a test which measures the antibodies IgG present in the blood against the novel coronavirus SARS-CoV2.